Invasive fungal infections among critically ill adult COVID-19 patients: First experiences from the national centre in Hungary - 02/12/21
Highlights |
• | We assessed invasive fungal infections (IFI) among critically ill COVID-19 patients. |
• | Among 90 eligible patients, 20 had IFI with an incidence of 2.02 episodes / 100 patient-days. |
• | Candidaemia was 45%, probable/putative invasive pulmonary aspergillosis was 80% among study patients. |
• | In-hospital all-cause mortality was 60% with a median time of 31.0±37.0 days. |
Abstract |
Introduction |
Data suggests that invasive fungal infections (IFI) might complicate COVID-19. Our goal was to describe characteristics of IFI among critically ill COVID-19 adults.
Methods |
A retrospective observational case-series analysis was done between March–July 2020. Consecutive patients with critical COVID-19 were eligible, and have been included when proven or putative/probable IFI could be confirmed during their course. For COVID-19 diagnosis, ECDC definitions and WHO severity criteria were followed. Candidaemia was diagnosed according to the ESCMID 2012 guideline. Invasive pulmonary aspergillosis (IPA) was defined following EORTC/MSG, ECMM/ISHAM and modified AspICU criteria. Outcome variables were rates of IFIs, in-hospital all-cause mortality, rate and time to negative respiratory SARS-CoV-2 PCR.
Results |
From 90 eligible patients, 20 (22.2%) fulfilled criteria for IFI. Incidence rate for IFI was 2.02 per 100 patient-days at ICU. Patients were mostly elderly males with significant comorbidities, requiring mechanical ventilation because of ARDS. IFI could be classified as candidaemia in 7/20 (40%), putative/probable IPA in 16/20 (80.0%). Isolated species of candidaemia episodes were Candida albicans (4/9, 44.4%), Candida glabrata (3/9, 33.3%), Candida parapsilosis (1/9, 11.1%), Candida metapsilosis (1/9, 11.1%). Mold isolates from lower respiratory tract were Aspergillus fumigatus, BAL galactomannan positivity was prevalent (16/20, 80.0%). Mortality was 12/20 (60.0%) with a median time to death of 31.0±37.0 (5–89) days. Only 9/20 (45.0%) patients reached SARS-CoV-2 PCR negativity after a median time of 20.0±12.0 (3–38) days.
Conclusion |
In this small cohort of critically ill COVID-19 adults, morbidity and mortality related to invasive fungal infections proved to be significant.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, Invasive fungal infection, Aspergillosis, Candidaemia, Cytokine storm
Abbreviations : AMB, ANI, ARDS, AS, BAL, BAR, BDG, BID, BSI, BW, CAS, CHF, COPD, COVID-19, CRP, CS, CT, DEX, DLBCL, DM, ECDC, EH, EUCAST, ECMM, F, FLU, FVP, GM, HCQ, HI, I, IDSA, IFI, IPA, ISA, ISHAM, ITR, iv., IVIG, L-AMB, LDH, LPV/r, LOS, M, MIC, MP, MYC, PCR, po., POS, QD, R, S, SARS-CoV-2, TID, TOC, VAP, VOR
Plan
Vol 31 - N° 4
Article 101198- décembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.